TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
PHOENIX, July 17, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) issued a statement today on its interactions with payors:
Insys, in concert with its business partners, is dedicated to helping patients navigate the complex payor environment that exists for patients as they seek to access the Insys products that their practicing health care providers have deemed appropriate or necessary for their treatment. As part of this endeavor, Insys is committed to establishing long-term partnerships in the healthcare community with public and private payors and operating with integrity and ethical standards that cultivate a culture of trust and transparency.
We believe that in the spirit of accountability, we have taken, and will continue to take, appropriate steps to learn from the past and to ensure that appropriate protocols and policies are in place at our Company. Where appropriate, Insys will vigorously advocate for fair patient access to medications, as well as vigorously defend itself within the legal and regulatory proceedings available to the Company.
About INSYS
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets one product, SUBSYS® (fentanyl sublingual spray) and has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
Investor Contact: Lisa M. Wilson 212-452-2793 E: [email protected]
